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Abstract
The 2009 H1N1 influenza A virus continues to circulate among the human population as the predominant H1N1 subtype.
Epidemiological studies and airborne transmission studies using the ferret model have shown that the transmission
efficiency of 2009 H1N1 viruses is lower than that of previous seasonal strains and the 1918 pandemic H1N1 strain. We
recently correlated this reduced transmission efficiency to the lower binding affinity of the 2009 H1N1 hemagglutinin (HA)
to a2R6 sialylated glycan receptors (human receptors). Here we report that a single point mutation (Ile219RLys; a base
pair change) in the glycan receptor-binding site (RBS) of a representative 2009 H1N1 influenza A virus, A/California/04/09 or
CA04/09, quantitatively increases its human receptor-binding affinity. The increased human receptor-affinity is in the same
range as that of the HA from highly transmissible seasonal and 1918 pandemic H1N1 viruses. Moreover, a 2009 H1N1 virus
carrying this mutation in the RBS (generated using reverse genetics) transmits efficiently in ferrets by respiratory droplets
thereby reestablishing our previously observed correlation between human receptor-binding affinity and transmission
efficiency. These findings are significant in the context of monitoring the evolution of the currently circulating 2009 H1N1
viruses.
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Introduction
On June 11, 2009, the World Health Organization raised the
global pandemic alert to phase 6, the pandemic phase [1], in
response to the emergence and global spread of a novel H1N1
influenza A virus (referred to henceforth as 2009 H1N1).
Phylogenetic analysis of the 2009 H1N1 virus indicated that it
emerged from reassortment of recent North American H3N2 and
H1N2 swine viruses (avian/human/swine ‘triple’ reassortant
viruses) with Eurasian avian-like swine viruses [2,3,4]. Owing to
a decline in the number of cases of 2009 H1N1 viral infection in
2010, the WHO declared the end of the 2009 H1N1 pandemic in
early August 2010. At this time, there were more than 600,000
laboratory confirmed cases of 2009 H1N1 infection and over
18,449 deaths as reported by the WHO [5]. Currently the 2009
H1N1 virus circulates as a seasonal strain causing dispersed
infection worldwide. A representative 2009 H1N1 strain, A/
California/04/09 (CA04/09), was chosen for trivalent seasonal flu
vaccine in 2010. Epidemiological [6,7,8] and transmission studies
using the ferret (Mustela putorius furo) animal model [9] have shown
that the efficiency of transmission of these viruses is lower than that
of the prototypic 1918 pandemic H1N1 (A/South Carolina/1/
1918 or SC18) and the 2007-08 seasonal H1N1 (A/Brisbane/59/
2007 or Bris07) influenza A viruses. Moreover the transmission of
2009 H1N1 virus via respiratory droplets was delayed after
exposure as compared to the Bris07 virus [9].
Using prototypic pandemic strains, such as 1918 H1N1 and
1957-58 H2N2, we have previously demonstrated that the binding
affinity of HA to human receptors is one important factor that
correlates with the transmissibility of the virus via respiratory
droplets in ferrets [10,11,12]. More recently, we extended this
finding to 2009 H1N1 by characterizing the glycan-receptor
binding specificity and affinity of the CA04/09 HA. These studies
demonstrated that CA04/09 HA bound specifically to human
receptors on a glycan array platform and on human upper
respiratory epithelia, and showed no detectable binding to a2R3
sialylated glycans (referred to as avian receptors) [9]. This
observed human receptor specificity of 2009 H1N1 HA was
consistent with similar studies by others [13]. The human
receptor-binding affinity of CA04/09 HA, however, was substan-
tially lower than that of SC18 HA [9]. The lower human receptor-
binding affinity of CA04/09 HA correlated with the observed
lower efficiency of airborne transmission of the CA04/09 virus.
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structural modeling of HA RBS and its interactions with glycan
receptor and HA sequence analysis we sought to identify mutations
in the RBS that would increase human receptor binding affinity of
CA04/09 HA. We demonstrate that a single Ile219RLys mutation
in the RBS of 2009 H1N1 HA (CA04/09mut1) substantially
increases its human receptor affinity in comparison with that of
CA04/09 HA. We tested the effect of this mutation experimentally
by site-directed mutagenesis and recombinant expression of mutant
HA and analyzed this mutant HA using a dose-dependent glycan
array assay to quantify HA-glycan binding affinity. Finally, we
constructed a CA04/09 virus harboring the Ile219RLys HA
mutation using reverse genetics and showed that this mutant virus
transmits efficiently via respiratory droplets in ferrets. Our findings
reemphasize the previously established correlation between human
receptor-binding affinity and transmission efficiency. Furthermore,
our approach to identify HA mutations that improve human
receptor affinity and transmissibility of the virus is significant in the
context of surveillance of the evolution of the currently circulating
2009 H1N1 virus.
Results
Rationale for designing Ile219RLys mutation on CA04/09
HA
The RBS of CA04/09 HA contains the hallmark amino acids
Asp190andAsp225thatarecharacteristicofallthehuman-adapted
H1N1 HAs [10,14,15,16]. Our previous comparison of amino acids
in the RBS of CA04/09 and SC18 HA revealed differences at
positions 145, 186, 189, 219, and 227 [17]. To understand the effect
of the amino acid differences on the molecular interactions in the
RBS, we constructed a structural model of CA04/09 HA with a
human receptor using the recently solved crystal structure of this
HA [18]. Analysis of this model indicates that Lys145 in CA04/09
HA providesanadditionalanchoring contact forthesialicacid.The
residues at 186, 187, and 189 are positioned to form an interaction
network with Asp190. The residues 219 and 227 in turn influence
the positioning of residue 186.
Comparison of residues 219 and 227 across a number of
human-adapted HA sequences reveals that either both amino
acids are hydrophobic, such as Ala219 and Ala227 as observed in
SC18 HA, or they are charged residues, such as Lys219 and
Glu227 as observed in Bris07 HA (Figure S1). In contrast, the
2009 H1N1 influenza A virus HAs have a combination of Ile219
and Glu227 that are highly conserved and that result in a set of
interactions that are neither fully hydrophobic nor fully charged
(Figure 1A). This mismatched combination of residues potentially
disrupts the positioning of residues 186, 189 and 190 that form a
stable network of inter-residue interactions. This network also
plays an important role in positioning Asp190 for optimal contact
with a2R6 glycans. To correct the mismatched combination of
residues in the RBS of CA04/09 HA, our strategy was to generate
a single mutant; Ile219RLys (CA04/09mut1), that would generate
a stable ionic interaction between Lys219 and Glu227. To confirm
this analysis, we constructed a homology-based structural of
CA04/09mut1 HA in complex with human receptor. Based on this
model we observed that Lys219 and Glu227 are positioned to
make ionic contacts that would facilitate the stabilization of
interaction network involving residues 186, 187, 189 and 190
(Figure 1B). We note that the mismatched combination can also
be fixed by making this interaction network hydrophobic.
However this would involve at least two amino acid substitutions,
Ser186RPro and Glu227RAla, to make this interaction network
similar to that observed in SC18 HA (Figure S1).
Quantifying human receptor-binding affinity of CA04/
09mut1 HA
A dose-dependent binding of HA to representative human and
avian receptors on a biotin-streptavidin based glycan array
platform permitted quantification of binding affinity using an
apparent binding constant Kd’ [10]. The parameter Kd’ was
calculated by fitting the binding data (over a range of HA
concentrations) using the Hill equation for multivalent binding
[10]. Given that HA is a homotrimer, a trimeric HA unit
comprises of three identical HA monomers (with one RBS per
monomer). The spatial arrangement of the biotinylated glycans in
the wells of the streptavidin plate array favors binding to only one
of the three HA monomers in the trimeric HA unit. Therefore in
order to specifically enhance the multivalency in the HA-glycan
interactions, the recombinant HA was pre-complexed with the
primary and secondary antibodies in the ratio of 4:2:1 (HA:
primary: secondary) as described previously [10,19]. The identical
spatial arrangement of 4 trimeric HA units in the pre-complex
relative to the glycans on the array platform, homogenizes the
avidity effects across different HAs and hence permits quantitative
comparison between glycan binding affinities of different HAs.
Using this approach, we performed a dose-dependent glycan
array analysis of CA04/09 and CA04/09mut1 HAs (Figure 2A–B).
In comparison with CA04/09 HA, which showed specific binding
to only 69SLN-LN, CA04/09mut1 HA showed binding to both the
representative human receptors (69SLN and 69SLN-LN) on the
array. No detectable binding to avian receptors was observed with
both CA04/09 and CA04/09mut1 HAs. To compare the binding
affinity of CA04/09 and CA04/09mut1 HAs to a representative
human receptor, we calculated the binding constant Kd’ from the
69SLN-LN binding curves (Figure 2C). The 69SLN-LN binding
affinity of CA04/09mut1 HA (Kd’,50 pM) is about 30-fold higher
than that of CA04/09 HA (Kd’,1.5 nM). The human receptor-
binding affinity of CA04/09mut1 HA quantified using Kd’ is in the
same range (picomolar) as that of SC18 HA (Kd’,6 pM).
Therefore fixing the mismatched combination of residues at 219
and 227 in the RBS of 2009 H1N1 HA substantially increases its
human receptor-binding affinity. We also verified that the dose-
dependent binding profile of recombinant CA04/09mut1 HA was
consistent with that of the whole virus harboring the Ile219RLys
HA mutation on our glycan array platform (Figure S2).
Binding of CA04/09mut1 HA to human tracheal tissue
sections
Human upper respiratory tissues are the primary targets for
infection by human-adapted influenza A viruses for efficient viral
transmission by respiratory droplets [10,20]. The tracheal tissue
section, a representative human upper respiratory tissue, has been
shown to predominantly express a2R6 sialylated glycan receptors
in the ciliated and non-ciliated (goblet) cells in the apical surface of
the pseudostratified epithelium [20,21,22,23,24]. In contrast, the
human alveolus, a representative deep lung tissue, has been shown
to predominantly express a2R3 sialylated glycan receptors
[20,22,25]. The binding of CA04/09 and CA04/09mut1 HAs to
physiological glycan receptors was assessed by staining human
tracheal and alveolar tissue sections with these HAs. Consistent
with their minimal a2R3 glycan receptor-binding on the array, no
visible alveolar staining was observed with these HAs (data not
shown). On the other hand, both CA04/09 and CA04/09mut1 HAs
stained the apical surface of the human tracheal epithelium
(Figure 2D) consistent with their human receptor-binding on the
array. Furthermore, CA04/09mut1 HA showed more intense
tracheal staining in comparison with CA04/09 HA, which
Receptor Binding and Transmission of 2009 H1N1
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both 69SLN and 69SLN-LN] and increased human receptor
affinity of the mutant HA on the glycan array. The sialic acid
specific binding of HAs to the tracheal tissue sections was
confirmed by loss of staining upon pre-treatment of the tissue
sections with Sialidase A (from Arthrobacter ureafaciens), an enzyme
that cleaves terminal sialic acid from both avian and human
receptors (data not shown).
Transmissibility of a reverse genetics wild-type and
mutant CA04/09 virus in ferrets
For respiratory droplet transmission experiments, three ferrets
were inoculated intranasally (i.n.) with 10
6 PFU (plaque forming
units) of virus. Approximately 24 hours later, inoculated-contact
animal pairs were established by placing a naı ¨ve ferret in each of
three adjacent cages with perforated sidewalls, allowing exchange
of respiratory droplets without direct or indirect contact [9].
Inoculated and contact animals were monitored for clinical signs
over a 16 day period and transmission was assessed by titration of
infectious virus in nasal washes and confirmed by the detection of
virus specific antibodies in convalescent sera.
Ferrets inoculated with the CA04/09 (rgCA04/09) virus, created
by reverse genetics, showed no substantial clinical signs and only
displayed transient weight loss during the first week of infection
(Table 1). Ferrets inoculated with rgCA04/09 virus shed high peak
mean titers of infectious virus in nasal washes as early as day 1 p.i.
(10
6.1–6.9 PFU/ml), that were sustained at titers of $10
2.9 PFU/ml
for 7 days p.i. The rgCA04/09 virus shedding showed similar
kinetics to mutant virus harboring the Ile219RLys amino acid
mutation in HA, which was sustained for 5 days in ferrets at titers
of $10
4.3 PFU/ml. Consistent with the experimental transmission
data obtained with wild type CA04/09 H1N1 virus [9], rgCA04/09
virus did not spread by respiratory droplet to every contact ferret
and transmission was delayed by five days post exposure in one of
two contact ferrets (Figure 3). Seroconversion confirmed the virus
shedding data of 2/3 transmission events (Table 1). The reduced
respiratory droplet transmission suggests that additional virus
adaptation in mammals may be required to reach the high-
Figure 1. Fixing the mismatched interaction in RBS of CA04/09 HA. A, Structural complex of RBS of CA04/09 HA with human receptor
(mismatched Ile219 - Glu227 interaction highlighted in red circle). B, RBS of CA04/09mut1 HA in complex with human receptor where Lys219
(highlighted in red) makes ionic contacts with Glu227. The structural complexes are shown in stereo with RBS represented as a cartoon schematic
with side chains of key amino acids. The substituted amino acids are labeled red. Stick representation of human receptor is shown with carbon atoms
in orange.
doi:10.1371/journal.pone.0017616.g001
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1918 pandemic virus [9,14]. Mutation of the HA at amino acid
position 219 (Ile219-.Lys) resulted in a virus (rgCA04/09 HA
Ile219Lys) that efficiently transmitted via respiratory droplets to all
of the contact ferrets which shed virus by day 3 post-contact (p.c.)
(Figure 3). Despite the differences in transmissibility of the
parental rgCA04/09 virus and the rgCA04/09 HA Ile219Lys mutant
virus, similar virus replication kinetics, and comparable levels of
fever induction and weight loss in ferrets were observed with both
viruses (Table 1). This pattern of transmission suggests that a
lysine at HA position 219 enhances transmission of the 2009
H1N1 virus through the air.
Discussion
The emergence of the 2009 H1N1 virus created a global
health concern given that it was a novel strain of influenza A
resulting from reassortment of gene segments derived from
Figure 2. Glycan receptor-binding property of CA04/09 and CA04/09mut1 HAs. Dose dependent direct glycan array binding of A, CA04/09
and B, CA04/09mut1 HAs. The mutant HA shows broader a2R6 sialylated glycan receptor specificity (shows binding to both 69SLN and 69SLN-LN)
compared to CA04/09 HA. Both HAs show minimal binding to a2R3 sialylated glycans. C,6 9SLN-LN binding curves of CA04/09, CA04/09mut1 and
SC18 HAs. The experimental data (disconnected markers indicated using ‘‘Data’’) is shown along with the theoretical binding curve (line indicated
using ‘‘Model’’) generated as described in Methods section. The calculated binding constant Kd’ values are shown on top of the binding curves. D,
Staining of human tracheal tissue sections with CA04/09 and CA04/09mut1 (green) against propidium iodide (red). The apical surface of the tracheal
tissue sections is indicated using a white arrow.
doi:10.1371/journal.pone.0017616.g002
Table 1. Replication and transmission of CA04/09 Ile219-.Lys HA mutant virus in ferrets.
Inoculated Animals RD Contact Animals
a
Virus
Weight
Loss (%)
c
Virus in nasal
wash
d Sneezing
e Sero-conversion
f
Weight
Loss (%)
c
Virus in nasal
wash
d Sneezing
e Sero-conversion
f
rgCA04/09 HA Ile219Lys
b 13.1 3/3 (6.4) 1/3 3/3 (640–1280) 8.5 3/3 (6.9) 1/3 3/3 (640–1280)
rgCA04/09 8.0 3/3 (6.6) 2/3 3/3 (640–1280) 7.1 2/3 (5.5) 1/3 2/3 (80–160)
aRD, respiratory droplet.
bThis experiment was performed using virus that was obtained from plaque purification and grown in MDCK cells.
cThe percentage mean maximum weight loss observed during the first 10 days post-inoculation.
dNumber of animals positive for infectious virus. Virus titers are expressed as mean log10 peak PFU/mL.
eNumber of animals in which sneezing was observed during the first 10 days after inoculation (sneezing was infrequent for all infected animals tested).
fHemagglutination inhibition (HI) assay was performed with homologous virus and turkey red blood cells. No. of positive animals and HI range indicated.
doi:10.1371/journal.pone.0017616.t001
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demonstrate that a single Ile219RLys amino acid change
stabilizes the ionic molecular interaction network involving
residues 219, 227 and 186 in the RBS of 2009 H1N1 HA that
in turn substantially increases its human receptor affinity in
comparison with wild-type HA. We also designed and tested
another mutant form of CA04/09 HA involving three mutations
to make this interaction network hydrophobic (similar to that in
SC18 HA) and showed that this mutant (CA04/09mut2)H Ah a d
substantially higher affinity than wild-type HA (Figure S3). Our
findings emphasize the importance of using a quantitative dose-
dependent binding assay with recombinant HA in order to
correlate biochemical glycan-binding affinity with molecular HA-
glycan interactions. The increased human receptor affinity of the
mutant HA correlated with efficient airborne transmission of a
virus that harbored this HA mutation in ferrets compared with
inefficient transmission of the wild-type rgCA04/09 virus. These
results highlight two important aspects of understanding
evolution of 2009 H1N1 virus. First, the inter-amino acid
interaction network in the RBS plays a key role in governing
human receptor binding affinity of HA. Second, the ferret
transmission results demonstrate that the quantitative human
receptor-binding affinity of HA is one of the key factors that
govern human host adaptation of the virus for efficient human-
to-human transmission.
It has been estimated that around 59% of United States
population has some immunity to the 2009 H1N1 virus either due
to pre-existing immunity, through vaccination, or due to the
infection with the pandemic virus [26]. Recent surveillance data
has shown that genetic variants of the 2009 H1N1 virus, carrying
mutations in HA, have already begun to dominate the later part of
2010 in Singapore, New Zealand and Australia [27]. Although
these mutations were found to be in the antigenic sites of HA, the
strains carrying these mutations were not antigenically different
from CA04/09 (no significant differences in hemagglutination
inhibition titers using ferret anti-sera raised to these viruses).
Previous studies using another H1N1 strain (A/Puerto Rico/8/34)
have shown that in order to escape polyclonal neutralizing
antibody challenge, this virus acquires mutations in its HA that
increased glycan receptor-binding affinity [28]. Given that the 219
position is a part of the antigenic loop and that a single amino acid
mutation in 219 increases human receptor-binding affinity, this
mutation may occur as a part of antigenic drift in the currently
circulating 2009 H1N1 strains. Moreover, the Ile219-.Lys
mutation requires a single nucleotide change, which also increases
the probability of such a mutation to occur. In summary, our study
provides a systematic approach to monitor the evolution of HA
mutations in the currently circulating 2009 H1N1 viruses that
would potentially result in strains with higher human receptor-
binding affinity and human-to-human transmissibility.
Figure 3. Respiratory droplet transmissibility of rgCA04/09 and rgCA04/09 HA Ile219Lys mutant virus. Three ferrets were intranasally
inoculated with 10
6 PFU of rgCA04/09 (A)o rrgCA04/09 HA Ile219Lys mutant virus (B). A naı ¨ve ferret was placed in an adjoining cage to each
inoculated ferret and viral shedding in nasal washes was assessed every other day for the inoculated (left) and contact (right) ferrets. Results from
individual ferrets are presented. Limit of detection is 10 PFU/mL.
doi:10.1371/journal.pone.0017616.g003
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Homology based structural modeling of CA04/09 and
CA04/09mut1
Using the SWISS-MODEL web-based automated homology-
modeling platform (http://swissmodel.expasy.org/) the homology
structural models of CA04/09, and CA04/09mut1 were construct-
ed. The template structure chosen by SWISS-MODEL was that of
a recently solved crystal structure of 2009 H1N1 HA (PDB ID:
3LZG). The starting pose of the HA-human receptor complex was
obtained by superimposing the modeled HA structure with the co-
crystal structure of 1918 H1N1 HA with human receptor (PDB
ID: 2WRG). The starting structural complex was subject to energy
minimization (500 steps of steepest descent followed by 500 steps
of conjugate gradient). The AMBER force-field was used to assign
potentials and charges. The default version of AMBER was
provided with the Discover module of InsightII molecular
modeling suite (Accelrys, San Diego, CA).
Cloning, baculovirus synthesis, expression and
purification of HA
Briefly, recombinant baculoviruses with WT or mutant HA
gene respectively, were used to infect (MOI=1) suspension
cultures of Sf9 cells (Invitrogen, Carlsbad, CA) cultured in BD
Baculogold Max-XP SFM (BD Biosciences, San Jose, CA). The
infection was monitored and the conditioned media was harvested
3–4 days post-infection. The soluble HA from the harvested
conditioned media was purified using Nickel affinity chromatog-
raphy (HisTrap HP columns, GE Healthcare, Piscataway, NJ).
Eluting fractions containing HA were pooled, concentrated and
buffer exchanged into 1X PBS pH 8.0 (Gibco) using 100K
MWCO spin columns (Millipore, Billerica, MA). The purified
protein was quantified using BCA method (Pierce).
Binding of recombinant CA04/09 and CA04/09mut1 HAs
to human tracheal tissue sections
Paraffinized human tracheal (US Biological) tissue sections were
deparaffinized, rehydrated and incubated with 1% BSA in PBS for
30 minutes to prevent non-specific binding. HA was pre-
complexed with primary antibody (mouse anti 6X His tag,
Abcam) and secondary antibody (Alexa fluor 488 goat anti mouse,
Invitrogen) in a molar ratio of 4:2:1, respectively, for 20 minutes
on ice. The tissue binding was performed over different HA
concentrations by diluting the pre-complexed HA in 1% BSA-
PBS. Tissue sections were then incubated with the HA-antibody
complexes for 3 hours at RT. The tissue sections were
counterstained by propidium iodide (Invitrogen; 1:100 in TBST).
The tissue sections were mounted and then viewed under a
confocal microscope (Zeiss LSM510 laser scanning confocal
microscopy). In the case of sialidase pretreatment, tissue sections
were incubated with 0.2 units of Sialidase A (recombinant from
Arthrobacter ureafaciens, Prozyme) for 3 hours at 37uC prior to
incubation with the proteins. This enzyme has been demonstrated
to cleave the terminal Neu5Ac from both Neu5Aca2R3Gal and
Neu5Aca2R6Gal motifs.
Dose dependent direct binding of CA04/09 and CA04/
09mut1 HAs
To investigate the multivalent HA-glycan interactions a
streptavidin plate array comprising of representative biotinylated
a2R3 and a2R6 sialylated glycans was used as described
previously [10] (Table S1). 39SLN, 39SLN-LN, 39SLN-LN-LN
are representative avian receptors. 69SLN and 69SLN-LN are
representative human receptors. The biotinylated glycans were
obtained from the Consortium of Functional Glycomics through
their resource request program. Streptavidin-coated High Binding
Capacity 384-well plates (Pierce) were loaded to the full capacity of
each well by incubating the well with 50 ml of 2.4 mMo f
biotinylated glycans overnight at 4uC. Excess glycans were
removed through extensive washing with PBS. The trimeric HA
unit comprises of three HA monomers (and hence three RBS, one
for each monomer). The spatial arrangement of the biotinylated
glycans in the wells of the streptavidin plate array favors binding to
only one of the three HA monomers in the trimeric HA unit.
Therefore in order to specifically enhance the multivalency in the
HA-glycan interactions, the recombinant HA proteins were pre-
complexed with the primary and secondary antibodies in the
molar ratio of 4:2:1 (HA: primary: secondary). The identical
arrangement of 4 trimeric HA units in the pre-complex for all the
HAs permit comparison between their glycan binding affinities.
A stock solution containing appropriate amounts of Histidine
tagged HA protein, primary antibody (Mouse anti 6X His tag IgG)
and secondary antibody (HRP conjugated goat anti Mouse IgG
(Santacruz Biotechnology) in the ratio 4:2:1 and incubated on ice
for 20 min. Appropriate amounts of pre-complexed stock HA
were diluted to 250 ml with 1% BSA in PBS. 50 ml of this pre-
complexed HA was added to each of the glycan-coated wells and
incubated at room temperature for 2 hrs followed by the above
wash steps. The binding signal was determined based on HRP
activity using Amplex Red Peroxidase Assay (Invitrogen, CA)
according to the manufacturer’s instructions. The experiments
were done in triplicate. Minimal binding signals were observed in
the negative controls including binding of pre-complexed unit to
wells without glycans and binding of the antibodies alone to the
wells with glycans. The binding parameters, cooperativity (n) and
apparent binding constant (Kd’), for HA-glycan binding were
calculated by fitting the average binding signal value (from the
triplicate analysis) and the HA concentration to the linearized
form of the Hill equation:
log
y
1{y

~n   log HA ½  ðÞ {log Kd
0 
where y is the fractional saturation (average binding signal/
maximum observed binding signal). The theoretical y values
calculated using the Hill equation:
y~
HA ½ 
n
HA ½ 
nzKd
0
(for the set of n and Kd’ parameters) were plotted against the
varying concentration of HA to obtain the binding curves for the
representative human receptor (69SLN-LN) in Figure 2C.
Construction of plasmids
The eight reverse-genetics plasmids used for the rescue of
recombinant influenza A/California/04/2009 (Cal/09) virus—
pDZ-Cal04-PB2, pDZ-Cal04-PB1, pDZ-Cal04-PA, pDZ-Cal04-
NP, pDZ-Cal04-HA, pDZ-Cal04-NA, pDZ-Cal04-M, and pDZ-
Cal04-NS - were constructed by methods described previously
[29,30]. The HA plasmid pDZ-Cal04-Ile219-.Lys was a
derivative of the wild-type (WT) HA segment. The mutation
Ile219-.Lys was created by altering the position 219 codon from
ATA to AAA using Stratagene QuickChange
site-directed
mutagenesis kit and pDZ-Cal04-HA as template.
Receptor Binding and Transmission of 2009 H1N1
PLoS ONE | www.plosone.org 6 March 2011 | Volume 6 | Issue 3 | e17616Rescue of recombinant influenza A viruses
The influenza A Cal/04 viruses were rescued as described
previously [31]. Briefly, 293T cells were transfected with the eight
pDZ-Cal04 vectors encoding each of the viral genomic RNA
segments. At 12 h post transfection, the 293T cells were co-
cultured with MDCK cells. The rescued viruses were further
isolated by plaque purification on MDCK cells. The coding
sequences of each PDZ construct and viruses generated by reverse
genetics were confirmed by automated sequencing performed at
the Centers for Disease Control and Prevention sequencing core
facility.
Inoculation of ferrets
The 2009 H1N1 virus animal experiments were conducted
under biosafety level 3 enhanced (BSL3+) laboratory conditions.
Male Fitch ferrets (Triple F Farms), 6 to 12 months of age that
were serologically negative by hemagglutination inhibition (HI)
assay for currently circulating influenza viruses were used in this
study. At the start of each experiment, all ferrets had body weights
greater than 1.0 kg, with a range of 1.01–1.57 kg. Ferrets were
housed throughout each experiment in cages within a Duo-Flo
Bioclean mobile clean room (Lab Products, Inc. Seaford, DE).
Baseline serum, temperature and weight measurements were
obtained prior to infection. Temperatures were measured using a
subcutaneous implantable temperature transponder (BioMedic
Data Systems, Inc.). Ferrets were inoculated intranasally with
10
6 PFU (plaque forming units) in a 1 ml volume, a dose reported
to consistently infect ferrets with human or avian influenza viruses
[32]. Ferrets were monitored for changes in body temperature and
weight, and the presence of the following clinical signs: sneezing,
lethargy, anorexia, nasal or ocular discharge, dyspnea, diarrhea,
neurological dysfunction [33]. Nasal washes were collected every
other day for at least 9 days post inoculation (p.i.) or contact (p.c.),
analyzed [34] and titrated by standard plaque assay.
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Transmission experiments
For the respiratory droplet transmission experiments, ferrets
were housed in adjacent transmission cages, each modified so that
a side wall was replaced with a stainless-steel, perforated wall with
holes 1–5 mm in diameter and spaced 3 mm apart to facilitate the
transfer of respiratory droplets through the air while preventing
direct contact between ferrets and indirect contact with the
bedding and food of neighbouring ferrets. A total of six ferrets
were used for each respiratory droplet transmission experiment
[33]. Twenty-four hours after inoculation (day 1 p.i. for the
inoculated ferrets and day 0 p.c. for the contact ferrets), three
naive ferrets were each placed in a cage adjacent to an inoculated
ferret. To prevent inadvertent physical transmission of virus by the
investigators, the contact ferrets were always handled first, and all
items that came into contact with the ferrets or their bedding were
decontaminated between each ferret. The use of the term
‘‘respiratory droplet transmission’’ throughout this report refers
to transmission in the absence of direct or indirect contact and
does not imply an understanding of the droplet size involved in
virus spread between ferrets. The ability of each virus to undergo
respiratory droplet transmission among ferrets was assessed by
measuring virus titres in nasal washes from contact animals every
other day for at least 11 days. HI analysis was also performed on
post-exposure ferret sera collected 18–21 days p.c. using 0.5%
turkey erythrocytes against homologous virus [34].
Supporting Information
Table S1 Expanded nomenclature of glycans used in the glycan
array.
(DOC)
Figure S1 ClustalW2 Sequence alignment CA04/09,
SC18 and Bris07 HAs. Only the HA1 part of the HA
comprising of the RBS is shown. The hallmark Asp190 and
Asp225 residues are highlighted in green. Residue positions
highlighted in gray represent the residues involved in positioning
Asp190. Residue positions 219 and 227 are highlighted in yellow to
indicate the mismatched combination of residues in CA04/09 HA.
(PDF)
Figure S2 Dose-dependent direct glycan array binding
of rgCA04/09 HA Ile219Lys mutant virus. The same glycan
array platform was used as that for the analysis with the HA. 50 ml
of the viruses (in HAU) (diluted in 1X PBS +1% BSA) were added
to each of the glycan – coated wells and incubated overnight at
4uC (to prevent sialic acid cleavage by viral neuraminidase). The
bound viruses were detected with ferret anti – CA04/09 antisera
(1:500 diluted in 1X PBS +1% BSA) and the secondary antibody
(goat anti – ferret HRP conjugated antibody from Abcam; 1:500
diluted in 1X PBS +1% BSA). The binding signals were
determined based on the HRP activity of the secondary antibody,
using the Amplex Red Peroxidase Assay (Invitrogen) according to
the manufacturer’s instructions. The assays were performed in
duplicate and appropriate controls were included. The binding
profile of this virus is consistent with that of the recombinant
CA04/09mut1 HA shown in Figure 2B.
(PDF)
Figure S3 Design and glycan array binding of CA04/
09mut2 HA. This mutant was designed to make the interaction
network involving residues 186, 219 and 227 hydrophobic. CA04/
09mut2 HA was recombinantly expressed and analyzed on the
glycan array similar to CA04/09mut1 HA. A, shows stereo
rendering of the RBS of CA04/09mut2 HA interacting with the
human receptor (stick representation with carbon atom colored in
orange). Three mutations Ser186Pro, Ala189Thr and Glu227Ala
in CA04/09mut2 HA make the inter-amino acid interaction
network identical to that observed in SC18 HA (Figure S1).
The mutated residues are highlighted in red. B, shows comparison
of 69SLN-LN binding curve between CA04/09 and CA04/09mut2
HA. Fixing the interaction network by making it hydrophobic also
substantially improves human receptor binding affinity.
(PDF)
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